ALT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Altimmune Inc (ALT) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock has shown significant recent price declines, bearish technical indicators, and mixed financial performance. While there are positive catalysts such as the planned Phase III trial and sufficient cash reserves, the high risk and volatility associated with the stock, coupled with no immediate trading signals, make it more prudent to hold off on investing right now.
The stock is in a bearish trend with a significant regular market decline of -17.92%. The MACD is negative and expanding downward, the RSI indicates oversold conditions at 13.483, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support levels are at 3.698 and 3.385, with resistance at 4.715 and 5.028.
Altimmune plans to initiate a global Phase III trial for pemvidutide in 2026, which could act as a significant growth driver.
The company has $340 million in cash reserves, sufficient to sustain operations into
FDA Breakthrough Therapy Designation for pemvidutide adds credibility to its pipeline.
Q4 GAAP EPS of -$0.27 missed expectations, and revenue remains negligible at $30,
The stock's price has declined significantly, with a -17.92% drop in the regular market session.
Bearish technical indicators and no recent congress trading data suggest limited immediate upside potential.
In Q4 2025, revenue increased by 420% YoY to $26,000, but net income remains negative at -$27.36 million, albeit improving by 18.02% YoY. EPS dropped to -0.27, down 18.18% YoY. Gross margin remains at 100%, but the company is still far from profitability.
Analysts have a positive long-term view on Altimmune, with Titan Partners initiating coverage with a Buy rating and a $7 price target, and Barclays assigning an Overweight rating with a $20 price target. However, the stock is considered high risk/high reward, dependent on the success of Phase III data for pemvidutide.
